La DGVS (Società Tedesca di Gastroenterologia, Malattie Digestive e Metaboliche) ha pubblicato le linee guida sulla steatosi epatica non alcolica.
La linea guida ha lo scopo di fornire una guida pratica sulla diagnosi, la terapia e la sorveglianza delle persone affette da NAFLD, compresa la modifica dello stile di vita e il trattamento farmacologico. Vengono forniti algoritmi diagnostici e terapeutici basati su comorbidità metaboliche e stadio della fibrosi per migliorarne l’applicabilità generale.
Leggi il full text dell’articolo:
- Updated S2k Clinical Practice Guideline on Non-alcoholic Fatty Liver Disease (NAFLD) issued by the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS)
F. Tacke, A. Canbay, H. Bantel, J. Bojunga, J. de Laffolie. et al.
Z Gastroenterol 2022; 60(09): e733-e801 DOI: 10.1055/a-1880-2388
Articoli correlati:
- AGA Clinical Practice Update | Diagnosis and management of nonalcoholic fatty liver disease in lean individuals.
- Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group – The Lancet Gastroenterology & Hepatology (free registration required)
- Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association – Arteriosclerosis, Thrombosis, and Vascular Biology
- Advancing the global public health agenda for NAFLD: a consensus statement – Nature Reviews Gastroenterology & Hepatology
- Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease – Gastroenterology
- Non-alcoholic fatty liver disease: A patient guideline – JHEP Reports
Click to rate this post!
[Total: 0 Average: 0]
